LENZ Therapeutics (LENZ) Competitors $29.96 +0.19 (+0.64%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$30.10 +0.14 (+0.47%) As of 08/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LENZ vs. PTCT, SWTX, MLTX, PTGX, AAPG, HCM, KYMR, CRNX, IMVT, and ALVOShould you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include PTC Therapeutics (PTCT), SpringWorks Therapeutics (SWTX), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), HUTCHMED (HCM), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), Immunovant (IMVT), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry. LENZ Therapeutics vs. Its Competitors PTC Therapeutics SpringWorks Therapeutics MoonLake Immunotherapeutics Protagonist Therapeutics Ascentage Pharma Group International HUTCHMED Kymera Therapeutics Crinetics Pharmaceuticals Immunovant Alvotech LENZ Therapeutics (NASDAQ:LENZ) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation. Is LENZ or PTCT more profitable? PTC Therapeutics has a net margin of 33.56% compared to LENZ Therapeutics' net margin of 0.00%. LENZ Therapeutics' return on equity of -25.63% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -25.63% -24.43% PTC Therapeutics 33.56%-78.56%32.11% Do analysts prefer LENZ or PTCT? LENZ Therapeutics presently has a consensus price target of $49.60, indicating a potential upside of 65.55%. PTC Therapeutics has a consensus price target of $69.38, indicating a potential upside of 33.10%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe LENZ Therapeutics is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17PTC Therapeutics 1 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has more volatility and risk, LENZ or PTCT? LENZ Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Do insiders & institutionals have more ownership in LENZ or PTCT? 54.3% of LENZ Therapeutics shares are owned by institutional investors. 6.9% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to LENZ or PTCT? In the previous week, PTC Therapeutics had 22 more articles in the media than LENZ Therapeutics. MarketBeat recorded 53 mentions for PTC Therapeutics and 31 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.63 beat PTC Therapeutics' score of 0.36 indicating that LENZ Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 8 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 12 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation & earnings, LENZ or PTCT? LENZ Therapeutics has higher earnings, but lower revenue than PTC Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ TherapeuticsN/AN/A-$49.77M-$1.90-15.77PTC Therapeutics$806.78M5.12-$363.30M$6.518.01 SummaryPTC Therapeutics beats LENZ Therapeutics on 8 of the 15 factors compared between the two stocks. Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENZ vs. The Competition Export to ExcelMetricLENZ TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$849.10M$3.00B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-15.7717.7428.8323.83Price / SalesN/A179.21372.0766.02Price / CashN/A41.9535.4557.96Price / Book4.148.508.275.54Net Income-$49.77M-$55.06M$3.25B$259.28M7 Day Performance-5.25%-3.99%-3.73%-4.68%1 Month Performance-3.23%9.58%4.29%4.36%1 Year Performance24.73%6.70%25.87%17.88% LENZ Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENZLENZ Therapeutics1.6846 of 5 stars$29.96+0.6%$49.60+65.6%+21.7%$849.10MN/A-15.77110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumePTCTPTC Therapeutics4.4836 of 5 stars$44.36-0.9%$65.77+48.3%+59.5%$3.55B$806.78M6.811,410Trending NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionSWTXSpringWorks TherapeuticsN/A$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230Upcoming EarningsMLTXMoonLake Immunotherapeutics2.721 of 5 stars$54.47-1.1%$73.14+34.3%+25.9%$3.53BN/A-23.682News CoveragePositive NewsUpcoming EarningsPTGXProtagonist Therapeutics2.1526 of 5 stars$56.26+2.0%$66.10+17.5%+41.8%$3.42B$434.43M75.01120Positive NewsUpcoming EarningsAAPGAscentage Pharma Group InternationalN/A$39.27+3.9%N/AN/A$3.30B$134.35M0.00600HCMHUTCHMED3.2074 of 5 stars$17.98+2.1%$23.50+30.7%-6.5%$3.07B$630.20M0.001,811Upcoming EarningsKYMRKymera Therapeutics3.5789 of 5 stars$44.20-3.5%$59.11+33.7%-3.4%$2.98B$58.89M-14.26170News CoveragePositive NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionCRNXCrinetics Pharmaceuticals3.3272 of 5 stars$30.30-2.2%$69.50+129.4%-46.5%$2.90B$760K-7.93210News CoverageUpcoming EarningsIMVTImmunovant1.6706 of 5 stars$16.76-1.1%$36.40+117.2%-45.6%$2.90BN/A-6.12120Upcoming EarningsALVOAlvotech3.3884 of 5 stars$9.81+2.1%$14.00+42.7%-24.0%$2.90B$491.98M26.511,032Positive News Related Companies and Tools Related Companies PTCT Competitors SWTX Competitors MLTX Competitors PTGX Competitors AAPG Competitors HCM Competitors KYMR Competitors CRNX Competitors IMVT Competitors ALVO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LENZ) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
